Fig. 2
From: The expansion of targetable biomarkers for CAR T cell therapy
Current CAR T cells in clinical trials. From the initial success of CD-19 CAR T cell therapy, several new biomarker targets have emerged and are being tested in clinical trials. This expansion of targets has expanded CAR T cell therapy to the treatment of not just hematological malignancies, but also to solid tumors as well